Stacy Roth
Psychiatric/Mental Health · Davenport, IANPI 1689077018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,972, 9.3 times the $211 reported in 2021.
Across 221 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$571
- Alkermes, Inc.$561
- Otsuka America Pharmaceutical, Inc.$372
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300
- Axsome Therapeutics, Inc.$290
- E.r. Squibb & Sons, L.L.C.$289
- plus $2K from 15 others
What the payments were for
- Food & beverage$4,23198%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $571 |
| Alkermes, Inc. | 32 | $561 |
| Otsuka America Pharmaceutical, Inc. | 25 | $372 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $300 |
| Axsome Therapeutics, Inc. | 9 | $290 |
| E.r. Squibb & Sons, L.L.C. | 12 | $289 |
| Johnson & Johnson | 13 | $262 |
| Vanda Pharmaceuticals Inc. | 12 | $243 |
| Teva Pharmaceuticals USA, Inc. | 12 | $202 |
| Lundbeck LLC | 12 | $195 |
| Neurocrine Biosciences, Inc. | 10 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $166 |
| Supernus Pharmaceuticals, Inc. | 6 | $162 |
| Braeburn Inc. | 1 | $125 |
| Indivior Inc. | 6 | $108 |
| Sunovion Pharmaceuticals Inc. | 6 | $87 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $67 |
| Almatica Pharma LLC | 3 | $67 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Orexo US, Inc. | 1 | $17 |
| Corium, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,306 in reported general payments places this provider in the 85th percentile of 443 psychiatric/mental health providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $303,000 |
| Austedo XrDeutetrabenazine | 15 | $136,166 |
| VraylarCariprazine Hcl | 83 | $128,361 |
| TrintellixVortioxetine Hydrobromide | 86 | $43,888 |
| RexultiBrexpiprazole | 29 | $43,487 |
| Invega SustennaPaliperidone Palmitate | 16 | $37,185 |
| CaplytaLumateperone Tosylate | 18 | $31,098 |
| Quetiapine Fumarate | 254 | $9,425 |
| Aripiprazole | 127 | $9,223 |
| Vilazodone Hcl | 78 | $8,096 |
| QuviviqDaridorexant Hcl | 15 | $7,599 |
| Lisdexamfetamine Dimesylate | 31 | $5,775 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,263 |
| Clozapine | 50 | $4,950 |
| Gabapentin | 167 | $4,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $176 | $303,00037 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $202 | $136,16615 claims |
| AbbVieVraylar | $571 | $128,36183 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $166 | $49,151100 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $372 | $43,48729 claims |
| Johnson & JohnsonInvega Sustenna | $262 | $37,18516 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $300 | $31,09818 claims |
| Almatica Pharma LLCSertraline Hcl | $67 | $845190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Davenport
- Daniel WesemannDavenport$15K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.